Mystic is developing a next generation drug delivery system (“INX2”) designed for lyophilized pharmaceuticals and biologic agents which normally require refrigeration or freezing to remain shelf stable.  The INX2 delivery system will allow drugs or biologic agents to remain in a stable freeze dried component form and be combined into final form as part of the drug administration procedure by the end user in a simple three step operation. This advanced drug delivery system will provide Mystic the capability to further expand its product pipeline into the multi-billon dollar lyophilized drug market.